Accéder au contenu
Merck

Intracavernosal etilefrine self-injection therapy for recurrent priapism: one decade of follow-up.

Urology (2005-05-11)
Claudio Teloken, Eduardo Porto Ribeiro, Mário Chammas, Patrick E Teloken, Carlos Ary Vargas Souto
RÉSUMÉ

Recurrent idiopathic priapism is a rare condition that, if not properly treated, may lead to impaired quality of life and erectile dysfunction. Treatment can be achieved by prevention of priapism episodes with systemic therapy or by early intervention with intracavernosal self-injection of sympathomimetic agents. We describe a case of a young patient with recurrent idiopathic priapism who has used etilefrine self-injection for the past 10 years with good efficacy and libido and erectile function preservation. This report suggests that this approach may be safely indicated in selected cases, particularly when sexual function preservation is a major concern.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Etilefrine hydrochloride, European Pharmacopoeia (EP) Reference Standard